Form 4 for KAPA Kairos Pharma, LTD.
Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-25 · accession 0001493152-24-047695 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-25 | 2024-11-25 | KAPA | Murali Ramachandran | VP of Research, Development | P - Purchase | $1.59 | +200 | 133.1K | +0.2% | +$318 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2024-11-25 | P | A | 200 | $1.59 | 133,057 | D | — | — |